Banco Bilbao Vizcaya Argentaria S.A. Raises Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 147,880 shares of the company’s stock after acquiring an additional 4,511 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. owned 0.15% of Neurocrine Biosciences worth $18,587,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox boosted its stake in shares of Neurocrine Biosciences by 83.5% during the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after purchasing an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP boosted its position in Neurocrine Biosciences by 44.0% during the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after acquiring an additional 640,556 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Neurocrine Biosciences by 3.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock worth $170,281,000 after acquiring an additional 49,088 shares during the period. Braidwell LP grew its stake in Neurocrine Biosciences by 32.2% in the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock worth $131,827,000 after acquiring an additional 290,135 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Neurocrine Biosciences by 8.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,159,367 shares of the company’s stock valued at $128,226,000 after acquiring an additional 89,271 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 300 shares of the company’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. This represents a 0.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the sale, the director owned 40,360 shares of the company’s stock, valued at approximately $6,127,455.20. This represents a 30.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $144.86 on Friday. The company has a market cap of $14.44 billion, a price-to-earnings ratio of 34.66, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $157.67. The stock’s 50-day moving average is $142.64 and its 200-day moving average is $132.68.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same quarter in the prior year, the company earned $1.81 EPS. The company’s revenue was up 27.8% on a year-over-year basis. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

NBIX has been the topic of several analyst reports. Citigroup raised their price objective on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Stifel Nicolaus increased their target price on Neurocrine Biosciences from $174.00 to $183.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Royal Bank Of Canada lifted their price target on Neurocrine Biosciences from $156.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, October 29th. Finally, Piper Sandler increased their price objective on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $170.53.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.